• Graphene Manufacturing Group has completed its acquisition of Cuspis Capital in a qualifying transaction between the companies
  • Graphene acquired 100 per cent of the shares of Cuspis and in exchange has issued 6,162,072 ordinary shares to the former shareholders of Cuspis
  • The transaction is subject to the final approval of the TSXV
  • Graphene intends to use the proceeds of the offering for general working capital purposes
  • Cuspis is a capital pool company
  • Cuspis Capital (CUSP.P) closed trading at $0.135 per share

Graphene Manufacturing Group has completed its acquisition of Cuspis Capital in a qualifying transaction between the companies.

In the transaction, Graphene acquired 100 per cent of the shares of Cuspis and in exchange has issued 6,162,072 ordinary shares of Graphene to the former shareholders of Cuspis.

The company also issued 604,500 stock options to former holders of stock options of Cuspis.

Each option allows the holder to purchase one share at a price of C$0.4963 until March 12, 2024.

The transaction is subject to the final approval of the TSXV. Once the transaction has been granted final approval, the combined company will begin trading under the symbol “GMG” and Cuspis’s shares will be delisted from the TSXV.

Graphene also appointed one of Cuspis’s directors, William Ollerhead, to its board of directors.

Cuspis had previously completed a non-brokered private placement financing of 3,077,000 subscription receipts, which were automatically converted to units of Graphene before the closing of the transaction.

Each unit consists of one share and half of one ordinary share purchase warrant.

Each whole warrant may be exercised for one share at C$1.00 per share for a period of eighteen months from the date of issuance.

GMG intends to use the proceeds of the offering for general working capital purposes.

Cuspis Capital (CUSP.P) closed trading at $0.135 per share.

More From The Market Online
stock market down

@ the Bell: TSX hits near-month high

The TSX rose near highs not seen in a month, but a split between indices capped gains as mining and energy were the only…

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.

Cloud DX signs fourth contract with a provincial health authority

Cloud DX (TSXV:CDX) signs its fourth contract with a provincial health authority for remote patient monitoring.

International Petroleum stock rallies on Q1 results

Canadian energy stock International Petroleum Corp. (TSX:IPCO) rose in Tuesday trading on its Q1 2024 financial...